@article{3080505,
    title = "Effect of infliximab on sight-threatening panuveitis in Behcet's disease",
    author = "Sfikakis, PP and Theodossiadis, PG and Katsiari, CG and Kaklamanis, P and and Markomichelakis, NN",
    journal = "The Lancet Neurology",
    year = "2001",
    volume = "358",
    number = "9278",
    pages = "295-296",
    publisher = "LANCET LTD",
    doi = "10.1016/S0140-6736(01)05497-6",
    abstract = "Permanent loss of vision resulting from relapsing ocular inflammation
occurs frequently in patients with Behcet’s disease, despite intensive,
chronic Immunosuppressive therapy. Since tumour necrosis factor (TNF)
might have an Important pathogenetic role in Behcet’s disease, we
decided to give a single Infusion of infliximab-a monoclonal antibody
against TNF-to five patients with relapsing panuveitis, at the immediate
onset of last relapse. Remission of ocular Inflammation was evident
within the first 24 h, and complete suppression was seen 7 days after
treatment In ail patients. No side-effects were noted. We suggest that
Infliximab is a rapid and effective new therapy for sight-threatening
ocular inflammation in Behcet’s disease."
}